Novo Nordisk files annual report with the SEC
31 Januar 2024 - 1:34PM
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 31 January 2024 – Novo
Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the
financial year 2023 with the US Securities and Exchange Commission
(SEC), incorporating by reference parts of the Novo Nordisk A/S
Annual Report 2022. The reports are available at the SEC's website,
www.sec.gov, as well as on novonordisk.com.
Shareholders may receive a hard copy of Novo Nordisk’s completed
audited financial statements free of charge upon request to
ancx@novonordisk.com.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
For more information, visit novonordisk.com, Facebook, Instagram,
X, LinkedIn and YouTube.
Contact for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Elizabeth
DeLuca (US)+1 609 580 9868edel@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
